According to data obtained from the British Society ofRheumatology Biologics Register, the mortality rate from ILD inpatients with rheumatoid arthritis (RA) treated with TNF-α inhibitorswas similar to those treated with conventional DMARDs.[22] A recentreview by Huang et al.[24] highlighted that the use of TNF-α inhibitorsin patients known to have RA-associated ILD may predispose themto more severe symptoms and even death.[24]. This evidence concerns the gene TNF and interstitial lung disease.